scholarly journals Peritoneal carcinomatosis index as a predictor of diaphragmatic involvement in stage III and IV ovarian cancer

2018 ◽  
Vol Volume 11 ◽  
pp. 2771-2777 ◽  
Author(s):  
Antoni Llueca ◽  
Anna Serra ◽  
Jose Luis Herraiz ◽  
Isabel Rivadulla ◽  
Luis Gomez ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peritoneal Carcinomatosis ◽  
Stage Iii ◽  
Peritoneal Carcinomatosis Index

The role of peritoneal carcinomatosis index in the operative treatment of ovarian cancer

2018 ◽  
Vol 16 (2) ◽  
pp. 82-88
Author(s):  
Włodzimierz Sawicki ◽  
◽  
Nabil Abdalla ◽  
Krzysztof Cendrowski ◽  
◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peritoneal Carcinomatosis ◽  
Operative Treatment ◽  
Peritoneal Carcinomatosis Index

Ovarian cancer with peritoneal carcinomatosis: Comparing of photodynamic treatment and HIPEC.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e17040-e17040
Author(s):  
Alexey Privalov ◽  
Andrey Vazenin ◽  
Ludmila Chernova ◽  
Alexey Taratonov ◽  
Tatiana Gubaydulina
Keyword(s):  
Ovarian Cancer ◽  
Adjuvant Chemotherapy ◽  
Peritoneal Carcinomatosis ◽  
Group Treatment ◽  
Treatment Options ◽  
Time To Progression ◽  
Photodynamic Treatment ◽  
Peritoneal Disease ◽  
Peritoneal Carcinomatosis Index ◽  
Neo Adjuvant Chemotherapy

e17040 Background: Peritoneal carcinomatosis is a very common by ovarian cancer (OC). Usual treatment`s approaches such as systemic drugs are not very effective. 5-year survival by OC depends of stage and are 15-20% in III stage and only 5% in IV stage. Most part of this patients die with progression of peritoneal disease. Standart treatment`s approach by OC is radical surgery with adjuvant chemotherapy. But in many cases this tactic can`t control peritoneal lesions and, therefore, outcomes. Methods: In our oncology center we are performing retrospective non-randomized prospective study comparing two different treatment options by ovarian`s peritoneal carcinomatosis - photodynamic therapy (PDT) and hyperthermic intraperitoneal chemotherapy (HIPEC). There were 25 patients in PDT-group and 21 patients in HIPEC-group. Treatment in PDT-group included 2-4 cycles of neo-adjuvant chemotherapy (cyclophosphamid+cisplatinum /CP/, n=7 or paclitaxel+cisplatinum /TC/, n=18 ), after which we performed surgery+PDT and then 4-6 cycles same chemotherapy. We used iv. photolon (Russia) as photosensitizer and 630-680 nm diod laser. Time of procedure was 20 minutes. Peritoneal Carcinomatosis Index (PCI) was 4,2 an averege (1-12). Treatment in HIPEC-group included 2-4 cycles of neo-adjuvant chemotherapy (cyclophosphamid+cisplatinum /CP/, n=21), after which we performed surgery+HIPEC and then 4-6 cycles the same chemotherapy. Medium PCI was 5,6 (2-11). We used “closed” HIPEC technique, with 3 inflow and 3 outflow catheters, Performer HT device by RanD and 7 liters of saline solution with 200 mg cisplatunum or 100 mg/m2 taxans were used. Results: There were 11 recurrence in PDT-group (44%) and 10 recurrence in HIPEC-group (38%), t=1,06. Median of time to progression was 11.6 months in PDT-group and 13,5 months in HIPEC-group. Median of overall surviving was 18,4 and 24,1 months respectively. Conclusions: Using of PDT by ovarian cancer with peritoneal carcinomatosis didn`t show increasing of overall survival. We can also notice the non-statistical tendency of increasing time to progression in HIPEC-group. We run our study further and hope to collect more data for analysis.

Prediction of 5-year survival in advanced-stage ovarian cancer patients based on computed tomography peritoneal carcinomatosis index

2016 ◽  
Vol 41 (11) ◽  
pp. 2196-2202 ◽  
Author(s):  
Daniel Diaz-Gil ◽  
Florian J. Fintelmann ◽  
Sanaz Molaei ◽  
Azadeh Elmi ◽  
Sandeep S. Hedgire ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Ovarian Cancer ◽  
Peritoneal Carcinomatosis ◽  
Cancer Patients ◽  
Advanced Stage ◽  
Peritoneal Carcinomatosis Index

scholarly journals Preclinical evaluation of local prolonged release of paclitaxel from gelatin microspheres for the prevention of recurrence of peritoneal carcinomatosis in advanced ovarian cancer

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kaat De Clercq ◽  
Feifan Xie ◽  
Olivier De Wever ◽  
Benedicte Descamps ◽  
Anne Hoorens ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Peritoneal Carcinomatosis ◽  
Advanced Ovarian Cancer ◽  
Recurrent Ovarian Cancer ◽  
Prolonged Release ◽  
Gelatin Microspheres ◽  
Drug Induced ◽  
Anticancer Efficacy ◽  
Peritoneal Carcinomatosis Index ◽  
Prevention Of Recurrence

Abstract Patients with advanced ovarian cancer develop recurrence despite initial treatment response to standard treatment of surgery and intravenous/intraperitoneal (IP) chemotherapy, partly due to a limited peritoneal exposure time of chemotherapeutics. Paclitaxel-loaded genipin-crosslinked gelatin microspheres (PTX-GP-MS) are evaluated for the treatment of microscopic peritoneal carcinomatosis and prevention of recurrent disease. The highest drug load (39.2 µg PTX/mg MS) was obtained by immersion of GP-MS in aqueous PTX nanosuspension (PTXnano-GP-MS) instead of ethanolic PTX solution (PTXEtOH-GP-MS). PTX release from PTX-GP-MS was prolonged. PTXnano-GP-MS displayed a more controlled release compared to a biphasic release from PTXEtOH-GP-MS. Anticancer efficacy of IP PTX-GP-MS (PTXEtOH-GP-MS, D = 7.5 mg PTX/kg; PTXnano-GP-MS D = 7.5 and 35 mg PTX/kg), IP nanoparticular albumin-bound PTX (D = 35 mg PTX/kg) and controls (0.9% NaCl, blank GP-MS) was evaluated in a microscopic peritoneal carcinomatosis xenograft mouse model. PTXnano-GP-MS showed superior anticancer efficacy with significant increased survival time, decreased peritoneal carcinomatosis index score and ascites incidence. However, prolonged PTX release over 14 days from PTXnano-GP-MS caused drug-related toxicity in 27% of high-dosed PTXnano-GP-MS-treated mice. Dose simulations for PTXnano-GP-MS demonstrated an optimal survival without drug-induced toxicity in a range of 7.5–15 mg PTX/kg. Low-dosed PTXnano-GP-MS can be a promising IP drug delivery system to prevent recurrent ovarian cancer.

Sign in / Sign up

Export Citation Format

Share Document